Expression and role of MHC class I-related chain in myeloma cells

Cytotherapy

Volumn 8, Issue 5, 2006, Pages 509-516

  Okamoto, M ^a   Inaba, T ^a   Yamada, N ^a   Uchida, R ^a   Fuchida, S I ^a   Okano, A ^a   Shimazaki, C ^a   Taniwaki, M ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

MHC class I related chain; Myeloma cells; NK cells; NKG2D

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; HLA ANTIGEN CLASS 1; INCADRONIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; RETINOIC ACID; THALIDOMIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MULTIPLE MYELOMA;

EID: 33750162373     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240600957586     Document Type: Article

References (33)

1. Trinchieri, G. (1989) Biology of natural killer cells Adv Immunol, 47, pp. 187-376.
2. Pende, D and Cantoni, C and Rivera, P and (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin Eur J Immunol, 31, pp. 1076-86.
3. Groh, V and Rhinehart, R and Secrist, H and (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB Proc Natl Acad Sci USA, 96, pp. 6879-84.
4. Pende, D and Rivera, P and Marcenaro, S and (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity Cancer Res, 62, pp. 6178-86.
5. Salih, HR and Antropius, H and Gieseke, F and (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia Blood, 102, pp. 1389-96.
6. Jinushi, M and Takehara, T and Tatsumi, T and (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid Int J Cancer, 104, pp. 354-61.
7. Vivier, E and Tomasello, E and Paul, P. (2002) Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition? Curr Opin Immunol, 14, pp. 306-11.
8. Bauer, S and Groh, V and Wu, J and (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA Science, 285, pp. 727-9.
9. Wu, J and Song, Y and Bakker, AB and (1999) An activating immunoreceptor complex formed by NKG2D and DAP10 Science, 285, pp. 730-2.
10. Groh, V and Bahram, S and Bauer, S and (1996) Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium Proc Natl Acad Sci USA, 93, pp. 12445-50.
11. Groh, V and Rhinehart, R and Randolph-Habecker, J and (2001) Costimulation of CD8 alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells Nat Immunol, 2, pp. 255-60.
12. Tieng, V and Le Bouguenec, C and du Merle, L and (2002) Binding of Escherichia coli adhesion AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA Proc Natl Acad Sci USA, 99, pp. 2977-82.
13. Das, H and Groh, V and Kuijl, C and (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function Immunity, 15, pp. 83-93.
14. Cunningham, D and Powles, R and Malpas, J and (1998) A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results Br J Haematol, 102, pp. 495-502.
15. Ludwig, H and Cohen, AM and Polliack, A and (1995) Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies Ann Oncol, 6, pp. 467-76.
16. Myeloma Trialists' Collaborative Group. (2001) Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients Br J Haematol, 113, pp. 1020-34.
17. Singhal, S and Mehta, J and Desikan, R and (1999) Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med, 341, pp. 1565-71.
18. Davies, FE and Raje, N and Hideshima, T and (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood, 98, pp. 210-16.
19. Kunzmann, V and Bauer, E and Feurle, J and (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood, 96, pp. 384-92.
20. Das, H and Wang, L and Kamath, A and Bukowski, JF. (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates Blood, 98, pp. 1616-18.
21. Alyea, E and Weller, E and Schlossman, R and (2003) Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: Impact of graft-versus-myeloma effect Bone Marrow Transplant, 32, pp. 1145-51.
22. Barlogie, B and Shaughnessy, J and Tricot, G and (2004) Treatment of multiple myeloma Blood, 103, pp. 20-32.
23. Lokhorst, HM and Wu, K and Verdonck, LF and (2004) The occurrence of graft versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma Blood, 103, pp. 4362-4.
24. Frohn, C and Hoppner, M and Schlenke, P and (2002) Anti-myeloma activity of natural killer lymphocytes Br J Haematol, 119, pp. 660-4.
25. Garcia-Sanz, R and Gonzalez, M and Orfao, A and (1996) Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications Br J Haematol, 93, pp. 81-8.
26. Gonzalez, M and San Miguel, JF and Gascon, A and (1992) Increased expression of natural-killer-associated and activation antigens in multiple myeloma Am J Hematol, 39, pp. 84-9.
27. King, MA and Radicchi-Mastroianni, MA. (1996) Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: Analysis by 4-colour flow cytometry Cytometry, 26, pp. 121-4.
28. Osterborg, A and Nilsson, B and Bjorkholm, M and (1990) Natural killer cell activity in monoclonal gammopathies: Relation to disease activity Eur J Haematol, 45, pp. 153-7.
29. Bahram, S and Bresnahan, M and Geraghty, DE and Spies, T. (1994) A second lineage of mammalian major histocompatibility complex class I genes Proc Natl Acad Sci USA, 91, pp. 6259-63.
30. Farag, SS and Fehniger, TA and Ruggeri, L and (2002) Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect Blood, 100, pp. 1935-47.
31. Cosman, D and Mullberg, J and Sutherland, CL and (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor Immunity, 14, pp. 123-33.
32. Takahashi, R and Shimazaki, C and Inaba, T and (2001) A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells Leuk Res, 25, pp. 77-83.
33. Carbone, E and Neri, P and Mesuraca, M and (2005) HLA class-I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells Blood, 105, pp. 251-8.